JP2024522086A5 - - Google Patents

Info

Publication number
JP2024522086A5
JP2024522086A5 JP2023572062A JP2023572062A JP2024522086A5 JP 2024522086 A5 JP2024522086 A5 JP 2024522086A5 JP 2023572062 A JP2023572062 A JP 2023572062A JP 2023572062 A JP2023572062 A JP 2023572062A JP 2024522086 A5 JP2024522086 A5 JP 2024522086A5
Authority
JP
Japan
Prior art keywords
sequence
manipulated
ribonucleic acid
guide ribonucleic
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522086A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031849 external-priority patent/WO2022256462A1/en
Publication of JP2024522086A publication Critical patent/JP2024522086A/ja
Publication of JP2024522086A5 publication Critical patent/JP2024522086A5/ja
Pending legal-status Critical Current

Links

JP2023572062A 2021-06-02 2022-06-01 クラスii、v型crispr系 Pending JP2024522086A (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202163196127P 2021-06-02 2021-06-02
US63/196,127 2021-06-02
US202163233653P 2021-08-16 2021-08-16
US63/233,653 2021-08-16
US202163261436P 2021-09-21 2021-09-21
US63/261,436 2021-09-21
US202163262169P 2021-10-06 2021-10-06
US63/262,169 2021-10-06
US202163280026P 2021-11-16 2021-11-16
US63/280,026 2021-11-16
US202263299664P 2022-01-14 2022-01-14
US63/299,664 2022-01-14
US202263308766P 2022-02-10 2022-02-10
US63/308,766 2022-02-10
US202263323014P 2022-03-23 2022-03-23
US63/323,014 2022-03-23
US202263331076P 2022-04-14 2022-04-14
US63/331,076 2022-04-14
PCT/US2022/031849 WO2022256462A1 (en) 2021-06-02 2022-06-01 Class ii, type v crispr systems

Publications (2)

Publication Number Publication Date
JP2024522086A JP2024522086A (ja) 2024-06-11
JP2024522086A5 true JP2024522086A5 (cg-RX-API-DMAC7.html) 2025-06-03

Family

ID=84324553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572062A Pending JP2024522086A (ja) 2021-06-02 2022-06-01 クラスii、v型crispr系

Country Status (9)

Country Link
US (1) US20240218339A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347816A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024522086A (cg-RX-API-DMAC7.html)
KR (1) KR20240017367A (cg-RX-API-DMAC7.html)
AU (1) AU2022284808A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024983A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219187A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014356A (cg-RX-API-DMAC7.html)
WO (1) WO2022256462A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178933A2 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
CA3252595A1 (en) * 2022-05-25 2023-11-30 Metagenomi Therapeutics, Inc. LIVER ENZYME EXPRESSION SUPPLEMENTATION
EP4705464A2 (en) * 2023-05-03 2026-03-11 Metagenomi, Inc. Base editing enzymes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178933A2 (en) * 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
MX2018010484A (es) * 2016-03-04 2019-01-10 Editas Medicine Inc Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
US11952408B2 (en) * 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
AU2019243315A1 (en) * 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
WO2020030984A2 (en) * 2018-08-09 2020-02-13 G+Flas Life Sciences Compositions and methods for genome engineering with cas12a proteins
JP7689949B2 (ja) * 2019-10-03 2025-06-09 アーティサン ディベロップメント ラブズ インコーポレイテッド 操作されたデュアルガイド核酸を有するcrisprシステム
CN110684823A (zh) * 2019-10-23 2020-01-14 海南大学 一种基于试纸条的Cas12a酶的微生物快速诊断技术
CN114867485A (zh) * 2019-10-31 2022-08-05 全国儿童医院研究所 Cd38敲除的原代和扩增的人nk细胞的生成
CN110904239B (zh) * 2019-12-25 2020-11-10 武汉博杰生物医学科技有限公司 肺癌相关分子标志物基因突变的检测试剂盒与检测方法
WO2022056489A1 (en) * 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd38 modification

Similar Documents

Publication Publication Date Title
US12391722B2 (en) Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA)
TWI835719B (zh) 經修飾之嚮導rna
FI3802807T3 (fi) Rna-ohjattuja nukleaaseja ja niiden aktiivisia fragmentteja ja variantteja ja menetelmiä niiden käyttämiseksi
CA3230927A1 (en) Guide rnas with chemical modification for prime editing
JP2024517607A5 (cg-RX-API-DMAC7.html)
JP2024506375A5 (cg-RX-API-DMAC7.html)
CN104711257B (zh) 用于乙型肝炎病毒感染治疗的导向rna靶点
Lennox et al. Chemical modifications in RNA interference and CRISPR/Cas genome editing reagents
CN109971755B (zh) 一种基于CRISPR/Cas9基因编辑技术的靶向肿瘤的基因治疗药物及其用途
US20240218339A1 (en) Class ii, type v crispr systems
US20060134658A1 (en) Use of RNA trans-splicing for generation of interfering RNA molecules
CN103667347A (zh) 一种高效表达抗癌基因的受特定miRNA调控的在胶质瘤细胞中特异增殖的腺病毒及其用途
Jedrzejczyk et al. Designing synthetic RNA for delivery by nanoparticles
JP2024532784A5 (cg-RX-API-DMAC7.html)
WO2020044186A2 (en) Products and compositions
Pérez et al. MicroRNA interference
Chang et al. CircRNA knockout/knockdown tools in molecular biology research
Roshan Mehr et al. Recent Developments in RNA Therapeutics for Humans Disorders
Martin et al. Nucleic Acid-Based Systems for Regenerative Medicine
WO2025180435A1 (en) Ligation of nucleic acid molecules and the use thereof for genome editing
HK40029231A (en) Stabilized nucleic acids encoding messenger ribonucleic acid (mrna)
Sopic RNA therapeutics in atherosclerosis
CN120004994A (zh) 一种胞嘧啶脱氨酶抑制剂SflSddi及其应用
CN116694638A (zh) 环状核酸应用-miRNA抑制剂
JP2026078993A (ja) 標的ヌクレオチド配列の改変のための二本鎖ヌクレオチド複合体